gms | German Medical Science

14. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie

Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie

15.11. - 16.11.2007, Frankfurt am Main

Change of drug therapy in the treatment of diabetics through Disease Management Programs (DMP)

Meeting Abstract

Suche in Medline nach

  • corresponding author T. Staffeldt - BKK Bundesverband, Essen
  • C. Kampmann - BKK Bundesverband, Essen
  • A. Grossmann - BKK Bundesverband, Essen

Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie e.V. (GAA). 14. Jahrestagung der Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie. Frankfurt am Main, 15.-16.11.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. Doc07gaa30

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/gaa2007/07gaa30.shtml

Veröffentlicht: 12. November 2007

© 2007 Staffeldt et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Aim of the study: To investigate the economic and qualitative impact of DMP on Drug Therapy for Diabetes Type II (according to § 137 SGB V)

Research design and methods: Comparison of characteristic values of a group of diabetics (Type II) which took part in the DMP with a control group that did not participated in the program. Selection of the control group were determined by the 1:1 Case Match-Method. Each participant was assigned to a control group participant with similar relevant sample characteristics (age, sex, morbidity and expense parameter).

Results: In comparison to the control group, the number of prescribed daily doses were more than doubled in the program group; prescription of Metformin, however, by 17%. Treatment of adipose diabetics with Metformin, both as monotherapy as well as in combination with Insulin or other oral antidiabetics, was in accordance with therapeutic guidelines which obviously were applied more often among the program participants.

Conclusion: The increase of prescription of Insulines does not come unexpected due to the intense medical attendance of the program participants. It can be assumed that with the extension of drug treatment on program participants, a quality treatment of diabetics can be guaranteed.